SpyGlass Pharma Surges Over 60% on First Trading Day
SpyGlass Pharma surged in its first day of trading at the end of last week, jumping more than 60% after pricing its initial public offering at $16, marking one of the strongest U.S. biotech debuts of the year and signaling renewed investor appetite for ophthalmology focused drug developers.LATEST IPOS AND DIRECT LISTINGS:Once Upon a Farmopened on February 6 at $21. The company had priced 10.997M shares, 7,631,537 shares of which were offered by Once Upon a Farm and 3,365,672 shares by certain existing stockholders, at $18.00, the midpoint of the $17.00-$19.00 target range. Once Upon a Farm, an organic food brand co-founded by actress Jennifer Garner, says its mission is to provide "organic, crave-worthy, snacks and meals for children of all ages."Agomabopened on February 6 at $14.70. The company had priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.SpyGlass Pharmaopened on February 6 at $24.00. The company had priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. SpyGlass Pharma is a late-stage biopharmaceutical company whose drug delivery technology is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.Forgent Power Solutionsopened on February 5 at $26. The company priced 56M shares at $27.00, at the midpoint of the $25.00-$29.00 target range. Forgent is a designer and manufacturer of electrical distribution equipment used in data centers, the power grid and energy-intensive industrial facilities.Eikon Therapeuticsopened on February 5 at $17.05. The company priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. Eikon is a late-stage clinical biopharmaceutical company whose initial focus is oncology, where it says it is advancing a pipeline of drug candidates "targeting areas of high unmet need in large indications" for various cancers.Bob's Discount Furnitureopened on February 5 at $17.00. The firm priced 19.45M shares at $17.00, the low end of the $17.00-$19.00 target range. Bob's is a national omnichannel retailer of value home furnishings with more than 200 showrooms across the United States.Veradermicsopened on February 4 at $34. The company had priced 15.08M shares at $17.00. The deal size was increased from 13.35M and priced above the $14.00-$16.00 range. Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing therapeutics for common aesthetic and dermatological conditions. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss.RECENT SPAC IPOS:Hennessy Capital Investment VIIIopened on February 5 at $10.02. Although the blank check company reserves the right to pursue an acquisition opportunity in any business or industry, the company intends to focus its search for a target business in the industrial innovation and energy transition sectors.Cantor Equity Partners VIopened at $10.13. The blank check company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, but the company intends to focus on a target in an industry where it believes the company's management teams' and affiliates' expertise will provide the company with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries.Iris Acquisition IIopened on February 3 at $9.96. Cohen & Company Capital Markets is acting as sole book-running manager for the offering.PERFORMANCE:Prices as of 11.00 am ET on Monday, February 9Once Upon a Farm – up over 15% at $24.26;Agomab – up more than 7% at $15.69;SpyGlass Pharma – fractionally down at $26.25;Forgent Power Solutions – up over 5% at $34.81;Eikon Therapeutics – up almost 4% at $15.02;Bob's Discount Furniture – up about 9% at $17.91;Veradermics – down almost 2% at $37.78.UPCOMING IPOS:Upcoming IPO and direct listings expected include OpenAI, AGI Inc, Speed Group, and Lendbuzz.Clickto see upcoming IPO calendar on TipRanks.OpenAIis accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.AGI Inc, or Agibank,has filed with the SEC for an initial public offering of its Class A common shares. The company intends to apply to list its Class A common shares on the New York Stock Exchange under the symbol "AGBK." The prospectus states, "Agibank Brazil is a privately held financial holding company and the holder of 100% of the outstanding share capital of Banco Agibank S.A., or Banco Agibank. In turn, Nuova Holding S.A., or Nuova, was a privately held, non-financial holding company controlled by our controlling shareholder, Mr. Marciano Testa... Our mission is to revolutionize financial services for the largest and fastest growing segment of Brazil's population: individuals who have been underserved by incumbent banks and have not been effectively reached by digital-only banks. We seek to make credit and banking solutions more accessible and affordable for the Brazilian consumers who we believe need it the most, including social security beneficiaries and private and public sector workers."Speed Groupfiled a prospectus for 2.5M share initial public offering. It expects the IPO price to be in the range of $4.00 to $5.00 per. The company's operating subsidiary, Speed Logistics, is an e-commerce logistics provider providing end-to-end logistics solution in Hong Kong, Europe and North America. The services include warehousing, customs clearance, air transportation, and final delivery from the European airports. For the years ended June 30, 2024 and 2025, Speed's revenues were $17.9M and $22.64M, respectively.Lendbuzz Inc.is offering an undetermined number of shares of its common stock and the selling stockholders identified in this prospectus are offering additional shares of common stock, according to an initial public offering prospectus filed with the SEC. The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol "LBZZ." The prospectus states: "Our mission is to offer fair access to credit for underserved populations. We are a financial technology company that utilizes artificial intelligence, or AI, and machine learning algorithms to better assess consumer credit risk and expand access to credit. We seamlessly process large sets of data through advanced computational approaches to more accurately predict a consumer's creditworthiness. Our business benefits both consumers through expanded access to credit, and auto dealerships via increased vehicle sales."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on OFRM
About OFRM
About the author

- Product Line Expansion: Once Upon a Farm has launched a new range of organic foods, including meat, meat & bone broth, legume blends, and smoothies with protein and probiotics, aimed at meeting the evolving nutritional needs of families from infants to school-aged children, which is expected to enhance the brand's competitiveness in the children's food market.
- Nutritional Innovation: The newly introduced meat and meat & bone broth products deliver at least 4g of high-quality protein per serving, sourced from hormone-free, antibiotic-free grass-fed beef and free-range chicken, designed to support children's growth and palate development, aligning with parents' preferences for fresh, healthy foods.
- Market Demand Response: According to Kantar Profiles/Mintel, 46% of U.S. parents consider protein an important attribute when choosing foods for babies and toddlers, and this product launch directly addresses that market demand, further solidifying Once Upon a Farm's position as a leader in children's nutrition.
- Mission Continuation: Once Upon a Farm is committed to providing organic, non-GMO, and no added sugar foods, aiming to support children's healthy growth through nutrient-rich products, reflecting the brand's long-term commitment to improving childhood nutrition.
- Product Line Expansion: Once Upon a Farm has launched a new range of organic foods, including meat, meat & bone broth, legume blends, and smoothies with protein & probiotics, aimed at meeting the nutritional needs of families from infancy to school age, which is expected to enhance the brand's competitiveness in the children's food market.
- Innovative Refrigerated Packaging: The newly introduced meat and bone broth pouches are the first organic meat products to utilize cold-pressure protection technology, ensuring nutrient retention and fresh flavor, addressing the preference of 72% of parents for fresh meat, thereby enhancing consumer trust.
- Nutritional Enhancement: Each smoothie delivers 4 grams of protein and probiotics to support active children's immune health, while the new Power Wheels snack bars also contain 4 grams of protein and 100% whole grain oats, catering to parents' demand for healthy snacks for their children.
- Clear Market Positioning: Once Upon a Farm's products are designed for babies aged 6 months and older and children aged 4 and up, aligning with 46% of U.S. parents' recognition of the importance of protein in children's foods, further solidifying the brand's leadership in the childhood nutrition sector.
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.

Stock Price Decline: Shares fell 15.2% to $17.16, marking a significant drop below the IPO price of $18.
Quarterly Results Impact: The decline in share price follows the release of quarterly results, indicating investor reaction to the company's performance.
- Sales Growth Highlight: Once Upon A Farm reported Q4 2025 sales of $64 million, reflecting a 30.1% increase driven by expanded distribution and significant household penetration, showcasing strong brand momentum and consumer trust in its mission-driven approach.
- Gross Margin Improvement: The gross margin for the quarter was 47.7%, up from 46.7% in the prior year, primarily due to lower trade spending and higher average selling prices, enhancing the company's profitability.
- Adjusted EBITDA Surge: Adjusted EBITDA reached $6.6 million, a substantial increase from $2.2 million in the previous year, although partially offset by rising SG&A expenses, indicating significant gross profit growth.
- Negative Market Reaction: Despite GAAP EPS of $0.11 beating consensus estimates, analysts expressed concerns that investors might be disappointed with the reported margin rate, leading to a 19.3% drop in premarket trading to $16.43, below the IPO range of $18.00 to $27.00.
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.










